Publication

An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands

van der Pol, S., Degener, F., Postma, M. J. & Vemer, P., Mar-2017, In : Value in Health. 20, 3, p. 388-396 9 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

van der Pol, S., Degener, F., Postma, M. J., & Vemer, P. (2017). An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands. Value in Health, 20(3), 388-396. https://doi.org/10.1016/j.jval.2016.10.015

Author

van der Pol, Simon ; Degener, Fabian ; Postma, Maarten J. ; Vemer, Pepijn. / An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands. In: Value in Health. 2017 ; Vol. 20, No. 3. pp. 388-396.

Harvard

van der Pol, S, Degener, F, Postma, MJ & Vemer, P 2017, 'An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands', Value in Health, vol. 20, no. 3, pp. 388-396. https://doi.org/10.1016/j.jval.2016.10.015

Standard

An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands. / van der Pol, Simon; Degener, Fabian; Postma, Maarten J.; Vemer, Pepijn.

In: Value in Health, Vol. 20, No. 3, 03.2017, p. 388-396.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

van der Pol S, Degener F, Postma MJ, Vemer P. An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands. Value in Health. 2017 Mar;20(3):388-396. https://doi.org/10.1016/j.jval.2016.10.015


BibTeX

@article{42eee36efa124dbaafb68365c403bb3b,
title = "An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands",
abstract = "Background: In September 2014, the PARADIGM-HF trial showed the heart failure drug combination sacubitril/valsartan to be superior to enalapril for patients with a reduced ejection fraction. Objectives: To determine the incremental cost-effectiveness of sacubitril/valsartan compared with enalapril in the Netherlands using the clinical data from the PARADIGM-HF trial. Methods: To compare sacubitril/valsartan and enalapril in a cost-effectiveness study, a Markov model was developed using the effectiveness data from the PARADIGM-HF trial. A health care payer's perspective was applied in the economic evaluation. The developed model was used to evaluate the costeffectiveness for sacubitril/valsartan at different per diem prices. Results: The base-case analysis showed that sacubitril/valsartan can be cost-effective at maximum daily costs of (sic)5.50 and (sic)14.14 considering willingness-to-pay thresholds of (sic)20,000 and (sic)50,000 per quality-adjusted life-year (QALY), respectively. Sensitivity analysis demonstrated the robustness of the model, identifying only the price of sacubitril/valsartan and the mortality within the sacubitril/valsartan group as significant drivers of the cost-effectiveness ratio. Sacubitril/valsartan was cost-effective at a willingness-to-pay threshold of (sic)20,000 per QALY ((sic)50,000 per QALY) in more than 80{\%} of the replications with certainty at the price point of(sic) ((sic)10). Conclusions: Sacubitril/valsartan can be considered a cost-effective treatment at a daily price of 5.25. Unless priced lower than enalapril (",
keywords = "economic evaluation, heart failure, valsartan/sacubitril, INTENSIVE-CARE UNITS, NEPRILYSIN INHIBITION, COST-EFFECTIVENESS, EJECTION FRACTION, ENALAPRIL, LCZ696, HOSPITALIZATION, POPULATION, PREVALENCE, IVABRADINE",
author = "{van der Pol}, Simon and Fabian Degener and Postma, {Maarten J.} and Pepijn Vemer",
note = "Copyright {\circledC} 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.",
year = "2017",
month = "3",
doi = "10.1016/j.jval.2016.10.015",
language = "English",
volume = "20",
pages = "388--396",
journal = "Value in Health",
issn = "1098-3015",
publisher = "ELSEVIER SCIENCE INC",
number = "3",

}

RIS

TY - JOUR

T1 - An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands

AU - van der Pol, Simon

AU - Degener, Fabian

AU - Postma, Maarten J.

AU - Vemer, Pepijn

N1 - Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

PY - 2017/3

Y1 - 2017/3

N2 - Background: In September 2014, the PARADIGM-HF trial showed the heart failure drug combination sacubitril/valsartan to be superior to enalapril for patients with a reduced ejection fraction. Objectives: To determine the incremental cost-effectiveness of sacubitril/valsartan compared with enalapril in the Netherlands using the clinical data from the PARADIGM-HF trial. Methods: To compare sacubitril/valsartan and enalapril in a cost-effectiveness study, a Markov model was developed using the effectiveness data from the PARADIGM-HF trial. A health care payer's perspective was applied in the economic evaluation. The developed model was used to evaluate the costeffectiveness for sacubitril/valsartan at different per diem prices. Results: The base-case analysis showed that sacubitril/valsartan can be cost-effective at maximum daily costs of (sic)5.50 and (sic)14.14 considering willingness-to-pay thresholds of (sic)20,000 and (sic)50,000 per quality-adjusted life-year (QALY), respectively. Sensitivity analysis demonstrated the robustness of the model, identifying only the price of sacubitril/valsartan and the mortality within the sacubitril/valsartan group as significant drivers of the cost-effectiveness ratio. Sacubitril/valsartan was cost-effective at a willingness-to-pay threshold of (sic)20,000 per QALY ((sic)50,000 per QALY) in more than 80% of the replications with certainty at the price point of(sic) ((sic)10). Conclusions: Sacubitril/valsartan can be considered a cost-effective treatment at a daily price of 5.25. Unless priced lower than enalapril (

AB - Background: In September 2014, the PARADIGM-HF trial showed the heart failure drug combination sacubitril/valsartan to be superior to enalapril for patients with a reduced ejection fraction. Objectives: To determine the incremental cost-effectiveness of sacubitril/valsartan compared with enalapril in the Netherlands using the clinical data from the PARADIGM-HF trial. Methods: To compare sacubitril/valsartan and enalapril in a cost-effectiveness study, a Markov model was developed using the effectiveness data from the PARADIGM-HF trial. A health care payer's perspective was applied in the economic evaluation. The developed model was used to evaluate the costeffectiveness for sacubitril/valsartan at different per diem prices. Results: The base-case analysis showed that sacubitril/valsartan can be cost-effective at maximum daily costs of (sic)5.50 and (sic)14.14 considering willingness-to-pay thresholds of (sic)20,000 and (sic)50,000 per quality-adjusted life-year (QALY), respectively. Sensitivity analysis demonstrated the robustness of the model, identifying only the price of sacubitril/valsartan and the mortality within the sacubitril/valsartan group as significant drivers of the cost-effectiveness ratio. Sacubitril/valsartan was cost-effective at a willingness-to-pay threshold of (sic)20,000 per QALY ((sic)50,000 per QALY) in more than 80% of the replications with certainty at the price point of(sic) ((sic)10). Conclusions: Sacubitril/valsartan can be considered a cost-effective treatment at a daily price of 5.25. Unless priced lower than enalapril (

KW - economic evaluation

KW - heart failure

KW - valsartan/sacubitril

KW - INTENSIVE-CARE UNITS

KW - NEPRILYSIN INHIBITION

KW - COST-EFFECTIVENESS

KW - EJECTION FRACTION

KW - ENALAPRIL

KW - LCZ696

KW - HOSPITALIZATION

KW - POPULATION

KW - PREVALENCE

KW - IVABRADINE

U2 - 10.1016/j.jval.2016.10.015

DO - 10.1016/j.jval.2016.10.015

M3 - Article

C2 - 28292483

VL - 20

SP - 388

EP - 396

JO - Value in Health

JF - Value in Health

SN - 1098-3015

IS - 3

ER -

ID: 40504522